

-continued

Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln
210						215					220				
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met
225				230					235						240
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro
			245					250						255	
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn
			260					265					270		
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Leu	Leu
			275				280					285			
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val
	290					295					300				
Phe	Ser	Cys	Ser	Val	Met	His	Gly	Ala	Leu	His	Asn	His	Tyr	Thr	Gln
305					310					315					320
Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys							
					325										

1-60. (canceled)

61. A bispecific antibody comprising the antigen binding region of an antibody which binds to human DR5, wherein bispecific antibody comprises an Fc region comprising a mutation of an amino acid position corresponding to E430, E345, or S440 in human IgG1, wherein the numbering is according to the EU Index.

62. The bispecific antibody of claim **61**, wherein (a) the bispecific antibody comprises an Fc region comprising a first and a second heavy chain, said first heavy chain comprising a mutation corresponding to F405L in human IgG1 and said second heavy chain comprising a mutation corresponding to K409R in human IgG1, or (b) wherein the bispecific antibody comprises an Fc region comprising a first and a second heavy chain, said first heavy chain comprising a mutation corresponding to K409R in human IgG1 and said second heavy chain comprising a mutation corresponding to F405L in human IgG1.

63. A method of treating an infectious disease, an autoimmune disease, or a cardiovascular anomaly comprising administering to a subject in need thereof an effective amount of a composition comprising a carrier and one or more antibodies comprising a Fc region of a human immunoglobulin IgG and an antigen binding region binding to human DR5, wherein the Fc region comprises a mutation of an amino acid position corresponding to E430, E345, or S440 in human IgG1, wherein the numbering is according to the EU Index.

64. The method of claim **63**, wherein the one or more antibodies comprises a variable heavy chain (VH) region and a variable light chain (VL) region selected from the group consisting of:

- a) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 5, the sequence FAS, and SEQ ID NO: 6, respectively;

- b) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 1, 8, and 3, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 5, the sequence FAS, SEQ ID NO: 6, respectively;

- c) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 10, 2, and 11, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 13, the sequence RTS, SEQ ID NO: 14, respectively; and

- d) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 21, the sequence GAS, SEQ ID NO: 22, respectively.

65. The method of claim **63**, wherein the one or more antibodies comprises a variable heavy chain (VH) region and a variable light chain (VL) region comprising the amino acid sequences selected from the group consisting of:

- a) SEQ ID NO:4 and SEQ ID NO:7, respectively;
- b) SEQ ID NO:9 and SEQ ID NO:7, respectively;
- c) SEQ ID NO:12 and SEQ ID NO:15, respectively;
- d) SEQ ID NO:19 and SEQ ID NO:23, respectively; and
- e) SEQ ID NO:20 and SEQ ID NO:23, respectively.

66. The method of claim **63**, wherein the Fc region of the one or more antibodies comprises the amino acid sequence selected from the group consisting of:

- a) SEQ ID NO:29;
- b) SEQ ID NO:30;
- c) SEQ ID NO:31;
- d) SEQ ID NO:32; and
- e) an amino acid sequence as defined in any one of a) to d) above having one to five mutations or substitutions in total across said sequence.